Dexrazoxane
DefinitionThis section has been translated automatically.
Precursor of a pharmaceutical, which is metabolized intracellularly to a chelating agent that is supposed to prevent the iron-mediated formation of free radicals. Dexrazoxan is a drug suitable for the treatment of extravasation by anthracyclines.
Pharmacodynamics (Effect)This section has been translated automatically.
- Prevention of the cardiotoxicity of anthracyclines by reducing the iron-dependent free radical oxidative stress associated with anthracycline-induced cardiotoxicity through iron chelation.
- Antineoplastic effect by inhibition of topoisomerase II. Both mechanisms may contribute to the protective effect against tissue destruction after extravasation by anthracyclines.
IndicationThis section has been translated automatically.
- Cardioxane: Approved for the prophylaxis of chronic cumulative cardiotoxicity by use of doxorubicin or epirubicin in patients with advanced and/or metastatic cancer after prior anthracycline-containing treatment.
- Savene: treatment of extravasation by anthracyclines.
Complication(s)This section has been translated automatically.
Hematotoxicity; neutrocytopenia and thrombocytopenia (about 50% of patients). Furthermore nausea/vomiting in about 1/3 of the patients; more rarely is an increase in the concentration of liver enzymes.
Notice! Regular monitoring of haematological parameters is urgently required.
Dosage and method of useThis section has been translated automatically.
- Cardioxane: 30 minutes before the anthracycline is administered as an i.v. infusion (15 minutes) in a dose corresponding to 20 times the doxorubicin equivalent dose or 10 times the epirubicin equivalent dose.
- Savene: Application is once daily i.v. for 3 consecutive days: 1000 mg/m2 KO on days 1 and 2 and 500 mg/m2 KO on day 3 The calculated dose must be administered over 1-2 hours as a slow intravenous infusion into a large vein of a limb/surface other than the limb/surface affected by lesions (extravasations).
Remember! The first infusion should be given within the first 6 hours after a paravenous infusion.
ContraindicationThis section has been translated automatically.
Hypersensitivity to the active substance or any of the other ingredients, women of childbearing age who do not use contraceptive methods, lactation or simultaneous vaccination with yellow fever vaccine.
PreparationsThis section has been translated automatically.
Savene (EMA approval); Cardioxane (approval in Germany)
Note(s)This section has been translated automatically.
Remember! Due to the cytotoxicity of Dexaroxan, sexually active men should practice effective contraception for at least 3 months after the end of treatment with Dexrazoxan.